Dose-Dense Temozolomide + Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
Neuro-oncology 2020 Oct 21;[EPub Ahead of Print], MR Gilbert, Y Yuan, J Wu, T Mendoza, E Vera, A Omuro, F Lieberman, HI Robins, ER Gerstner, J Wu, PY Wen, T Mikkelsen, K Aldape, TS ArmstrongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.